(Q44667926)

5 December 2017

0 references

Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia (English)

1 reference

5 December 2017

0 references

0 references

1 reference

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia

series ordinal

1

1 reference

5 December 2017

1 December 2003

1 reference

Australian and New Zealand Journal of Psychiatry

5 December 2017

1 reference

5 December 2017

37

1 reference

5 December 2017

6

1 reference

5 December 2017

641-656

1 reference

The cross-national epidemiology of panic disorder

5 December 2017

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Six-month prevalence of psychiatric disorders in three communities 1980 to 1982.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Is the course of panic disorder the same in women and men?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Course and outcome in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

The role of life events in the onset of panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Panic attacks in the community. Social morbidity and health care utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

The Zurich Study. IX. Panic disorder and sporadic panic: symptoms, diagnosis, prevalence, and overlap with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Prevalence of mental disorders and psychosocial impairments in adolescents and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Quality of life in panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Comorbidity of major depression and panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Prevalence, patterns and role of personality disorders in panic disorder patients with and without comorbid (lifetime) major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Panic disorder and suicide attempt. A reanalysis of data from the Epidemiologic Catchment Area study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Suicidality in panic disorder: a comparison with schizophrenic, depressed, and other anxiety disorder outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Panic attacks and suicide attempts in mid-adolescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Interoceptive exposure versus breathing retraining within cognitive-behavioural therapy for panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Panic provocation in the treatment of agoraphobia: a preliminary investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Randomised controlled assessment of non-directive psychotherapy versus routine general-practitioner care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Double-blind pilot trial of desipramine versus fluoxetine in panic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Lorazepam vs. alprazolam in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Controlled discontinuation of benzodiazepine treatment for patients with panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Discontinuation reactions to alprazolam in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Emergence of hostility during alprazolam treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Seizures following the withdrawal of alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Moclobemide for anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

The benefit of an insight-oriented and experiential approach on panic and agoraphobia symptoms. Results of a controlled comparison of client-centered therapy alone and in combination with behavioral exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Effects of Clonidine on Anxiety Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Subclinical symptoms of panic disorder: new insights into pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Long-term effects of behavioural treatment for panic disorder with agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

The assessment of panic using self-report: a comprehensive survey of validated instruments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Classification in psychiatry: ICD-10 versus DSM-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

The Mobility Inventory for Agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

The Language Barrier in Evaluating Spanish-American Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Clinical relevance of contemporary cultural psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FJ.1440-1614.2003.01254.X

10.1080/J.1440-1614.2003.01254.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference

PubMed ID

14636376